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Introduction {#s1}
============

Introduction of antiretroviral therapy (ART) all over the world has dramatically improved the health condition of HIV-1 infected individuals [@pone.0105790-Autran1]. This is reflected by way of sharp fall in mortality and morbidity associated with HIV-1/AIDS [@pone.0105790-Palella1]. Developing countries like India with heavy burden of HIV-1 population has also seen a gradual increase in use of ART and at present 0.6 million individuals are taking 1^st^ line ART [@pone.0105790-National1]. In order to sustain the success of this ART program it is important to monitor the patients in regular interval and keep switching the treatment regimen [@pone.0105790-Hammer1] as per need of the patient. As HIV-1 drug resistance is one of the formidable causes for treatment failure and choice for drugs are limited, there is need for a cost effective HIV-1 drug resistance monitoring system in resource limited settings like India [@pone.0105790-Bertagnolio1].

In order to monitor progression of disease in patients undergoing ART, a number of tools such as point-of-care CD4 testing, HIV-1 viral load testing and HIV-1 drug resistance analysis using plasma/dried blood spots are being evaluated for their suitability in resource limited setting in terms of cost and efficiency [@pone.0105790-Mehta1]--[@pone.0105790-Jani1]. Among these, HIV-1 drug resistance genotyping assay is of special relevance because of its use in monitoring transmitted drug resistance mutations in drug naïve individuals [@pone.0105790-Bennett1]. Information regarding emergence and prevalence of HIV-1 drug resistance mutations is important in guiding the national strategy for implementing ART program in resource limited settings with limited treatment options [@pone.0105790-Bennett2].

The commercial kits available for HIV-1 drug resistance genotyping are expensive and the prohibitive running costs hinder their routine use in resource limited countries like India [@pone.0105790-Saravanan1]. These assays are designed specifically for HIV-1 subtype B strains predominant in North America and Europe. Hence, genetic diversity of non B subtype HIV-1 strains prevalent in Africa and Asia pacific region poses challenge for use of these kits in such geographical regions [@pone.0105790-Peeters1]. This has led to continuous efforts to develop homebrew HIV-1 drug resistance genotyping assays across the world with varying success [@pone.0105790-Parkin1]--[@pone.0105790-Wallis1]. India is dominated by HIV-1 subtype C virus [@pone.0105790-Shen1]. Recently we have demonstrated a definite geographical bias of nucleotide sequence motifs within specific regions of HIV-1 genome [@pone.0105790-Acharya1] that indicate the need for not only cost effective but also a region-specific, high quality HIV-1 drug resistance assay for periodic monitoring of patients undergoing ART.

In this study we report a cost effective HIV-1 drug resistance genotyping assay for Indian population that is validated against US-FDA approved ViroSeq Genotyping System 2.0 (Celera Diagnostics, USA) and demonstrate its efficiency in identifying all drug resistant mutations related to NRTI, NNRTI and PI classes of antiretroviral drugs.

Materials and Methods {#s2}
=====================

Study Population {#s2a}
----------------

Plasma samples collected form 20 treatment experienced HIV-1 positive patients from India and those experiencing virologic failure were used as reference panel in this study. The clinical characteristics of this resource population are described in [**Table 1**](#pone-0105790-t001){ref-type="table"}.

10.1371/journal.pone.0105790.t001

###### Clinical characteristics and subtype of the reference panel.

![](pone.0105790.t001){#pone-0105790-t001-1}

  Sample ID     Plasma Viral Load(HIV-1 RNA copies/ml)    ART Regimen    HIV-1subtype   Plasmagenotype  
  ------------ ---------------------------------------- --------------- -------------- ---------------- ----
  HIV-IN-638                   1680600                    AZT+3TC+EFV         C               \+         \+
  HIV-IN-642                   2576440                    AZT+3TC+NVP         C               \+         \+
  HIV-IN-648                   6598655                    AZT+3TC+EFV         C               \+         \+
  HIV-IN-652                   1154880                    TDF+3TC+NVP         C               \+         \+
  HIV-IN-655                   2237655                   ATV/r+TDF+3TC        C               \+         \+
  HIV-IN-661                    875600                    TDF+3TC+EFV         C               \+         \+
  HIV-IN-662                    165895                    AZT+3TC+NVP         C               \+         \+
  HIV-IN-665                    436278                    TDF+3TC+NVP         C               \+         \+
  HIV-IN-669                    278354                    AZT+3TC+EFV         C               \+         \+
  HIV-IN-670                    122400                    AZT+3TC+EFV         C               \+         \+
  HIV-IN-672                    24388                     TDF+3TC+EFV         C               \+         \+
  HIV-IN-675                    46544                    ATV/r+TDF+3TC        C               \+         \+
  HIV-IN-678                    75390                     TDF+3TC+EFV         C               \+         \+
  HIV-IN-679                    33175                     TDF+3TC+NVP         C               \+         \+
  HIV-IN-683                    12540                     AZT+3TC+NVP         A               \+         \+
  HIV-IN-685                     8755                     AZT+3TC+NVP         C               \+         \+
  HIV-IN-688                     4655                    ATV/r+TDF+3TC        C               \+         \+
  HIV-IN-690                     2690                     AZT+3TC+EFV         C               \+         \+
  HIV-IN-694                     2100                     AZT+3TC+EFV         A               \+         \+
  HIV-IN-695                     1350                     AZT+3TC+NVP         C               \+         \+

"+": Positive amplification; ART: Anti retroviral therapy; AZT: Zidovudine; 3TC: Lamivudine; EFV: Efavirenz; NVP: Nevirapine; TDF: Tenofovir; ATV/r: Atazanavir/r.

The clinical panel used in this study comprised of 225 samples. The patients were enrolled during the period of May 2012 and Septembers 2013 from India and all were under first-line of antiretroviral therapy for more than 6 months and failing the highly active anti retroviral therapy \[HAART\] as per current HIV treatment guidelines followed in India [@pone.0105790-Kumarasamy1]. After developing the in-house genotyping assay described here, this clinical panel was used to study the prevalence of HIV-1 drug resistance mutations in India. The details of demographic and clinical characteristics of these 225 samples are summarized in [**Table 2**](#pone-0105790-t002){ref-type="table"}. The study was duly approved by SN Gene laboratory clinical research, institutional bio-safety and bio-ethics committee (Approval number DGL/2012/WY07). Written informed consent was obtained from all participants enrolled in this program.

10.1371/journal.pone.0105790.t002

###### Demographic characteristics and laboratory results of the clinical panel.
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  Variables                                   Summary, n = 225
  ----------------------------------------- --------------------
  Age (yrs), median (IQR)                       32 (26--41)
  Gender, n (%):                            
  Male                                          121 (53.7%)
  Female                                         90 (40.0%)
  Child                                          14 (6.3%)
  Median CD4T cellcount, cells/µl (IQR)        137 (100--180)
  Median Viral load, log10copies/ml (IQR)    5.055 (4.39--5.47)
  Risk exposure, n (%):                     
  Heterosexual (%)                              115 (51.2%)
  Bisexual (%)                                   40 (17.7%)
  MSM (%)                                        50 (22.2%)
  MTC (%)                                        20 (8.9%)
  Other co-infections, n (%)                     48 (21.3%)
  HIV-1 subtypes, n (%):                    
  Subtype C                                     176 (85.5%)
  Subtype A                                      29 (14.0%)
  Subtype B                                       1 (0.5%)
  Treatment regimen:                        
  AZT, 3TC, EFV                                 35 (15.56%)
  AZT, 3TC, NVP                                 50 (22.22%)
  TDF, 3TC, NVP                                 45 (20.00%)
  TDF, 3TC, EFV                                 35 (15.56%)
  ATV/r, TDF, 3TC                               35 (15.56%)
  LPV/r, AZT, 3TC                               25 (11.10%)

IQR: Interquartile range; MSM: Men who have Sex with Men; MTC: Mother to Child Transmission; AZT: Zidovudine; 3TC: Lamivudine; EFV: Efavirenz; NVP: Nevirapine; ATV/r: Atazanavir/r; LPV/r: Lopinavir/r.

Specimen Collection and storage {#s2b}
-------------------------------

Ten ml of blood was collected from each panel members in K~2~-EDTA vacutainer tubes (Becton Dickinson, San Diego, California, USA). Out of this, 2--3 ml was used for CD4+ T cell counting and the remaining for plasma separation. Plasma samples were stored in 1 ml aliquots at −20°C till further use.

HIV-1 Viral Load and CD4+ T cell count estimation {#s2c}
-------------------------------------------------

The viral load of reference and clinical panel samples were determined using *artus* HIV-1 RG RT-PCR kit (Qiagen, Germany) while CD4/CD8+ T cell counts were estimated using a FACS CALIBUR flow cytometer (BD Biosciences, California, USA), both according to respective manufacturer's instructions.

ViroSeq genotyping system {#s2d}
-------------------------

The HIV-1 drug resistance genotyping of reference panel samples were carried out using US-FDA approved ViroSeq genotyping system according to manufacturer's instructions. ViroSeq HIV-1 genotyping system software v2.6 and Stanford HIVDB [@pone.0105790-Liu1] were used for drug resistance interpretation.

RNA Extraction and In-house HIV-1 Drug Resistance Genotyping {#s2e}
------------------------------------------------------------

The drug resistance genotyping analysis of reference as well as clinical panel samples were carried out according to the method described as follows:

HIV-1 RNA was extracted from plasma samples stored at −20°C within 7 days of collection using a QIAamp Viral RNA mini kit (Qiagen, Germany) and subjected to one step RT PCR. This was followed by nested PCR to generate a 1614 bp amplicon that covered the entire protease gene and more than 300 initial amino acids of reverse transcriptase gene. All primers described in this study were designed using HIV-1 *pol* gene sequences reported from India and available from NCBI GenBank.

Briefly, the extracted RNA samples were reverse transcribed and then amplified using SuperScript III One-Step RT-PCR System (Life Technologies, Foster City, USA). Fifty µl of a reaction mixture comprised of 25 µl of 2X reaction mix, 2 µl of enzyme mix (SuperScript III RT and Platinum Taq), 20 µl of RNA and each primers (forward and reverse) at a final concentration of 10 pmoles per reaction respectively. The primer sequences used in the reaction were: 5′- GCTGTTGGAAATGTGGAA--3′ (forward) and 5′- TGGCTTGCCAATAGTCTGT--3′ (reverse). The thermal cycling profile comprised of 60 minutes of reverse transcription at 45°C followed by 5 minutes of heating at 95°C and 35 subsequent cycles of PCR amplification, each comprising of 95°C for 30 seconds, 56°C for 45 seconds, and 72°C for 180 seconds followed by a 10 minutes final extension at 72°C.

For nested PCR, 5 µl of the 1^st^ round PCR product was used as template. The reaction mixture comprised of 25 µl 2X PCR Mix v.2.0 (TaKaRa-bio, CA, USA), 10 pmoles of each primer (forward and reverse) and nuclease free water to make the volume to 50 µl. The thermal cycling profile comprised of an initial denaturation step of 5 minutes at 95°C followed by 35 cycles of PCR amplification, each comprising of 95°C for 30 seconds, 59°C for 45 seconds, and 72°C for 180 seconds followed by 10 minutes of final extension at 72°C. The primer sequences used for the nested PCR reaction were 5′- GTGGAAAGGAAGGACACCA--3′ (forward) and 5′- TGTTTTACATCATTAGTGT--3′ (reverse). PCR products generated from nested PCR were run on a 1% agarose gel (Promega Corporation, Madison, USA), stained with ethidium bromide (0.5 µg/ml), visualized under a UV source (260 nm) and documented using an automated gel documentation system (BIORAD, USA). For quality control, negative, low positive and high positive control samples were run with every batch of reactions.

PCR products generated from nested PCR were purified using a PureLink Quick PCR Purification Kit (Invitrogen, USA) and subjected to double strand DNA sequencing using 4 pairs of sequencing primers. The sequencing reactions were carried out using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) as per manufacturer's instructions followed by capillary electrophoresis performed on an ABI PRISM 3500 Dx Genetic Analyzer (Applied Biosystems, USA). The nucleotide sequences of all oligonucleotide primers used to generate bidirectional sequence data, apart from those used for nested PCR amplification, were as follows: 5′- GTACAGTATTAGTAGGAC--3′, 5′- ATATCAATATAATGTGC--3′, 5′- ATGATATACAGAAGTTAGT--3′, 5′- TACTGGTACAGTTTCAATA--3′, 5′- TGTTTATACTAGGTATGGT--3′ and 5′- CTGGCAGCTGTATAGGCTGTA--3′.

The raw nucleotide sequence data generated were manually edited and assembled into a single contiguous sequence, archived and compared with standard HIV-1 reference strain sequence (HXB2) to obtain the nucleotide variation data. For determining HIV-1 subtype and obtaining HIV-1 drug resistance mutation profile, the edited nucleotide sequences were analyzed using Stanford HIVDB [@pone.0105790-Liu1]. Single letter amino acid codes were used throughout the manuscript as per the standard IUPAC nomenclature.

Validation criteria {#s2f}
-------------------

Validation of the assay methodology described in this study was performed according to WHO guidelines [@pone.0105790-WHO1].

Accuracy {#s2g}
--------

Accuracy of the assay was evaluated by analyzing the degree of concordance between drug resistance mutations identified by ViroSeq genotyping system and in-house assay using the reference panel as per IAS mutation list [@pone.0105790-Johnson1].

Sensitivity {#s2h}
-----------

The sensitivity of the assay was evaluated using 5 clinical samples taken from the reference panel. A dilution series was prepared for each sample with viral load of 100000, 10000, 5000, 1000 and 500 HIV-1 RNA copies/ml and tested in triplicate using the in-house assay protocol.

Precision and Reproducibility {#s2i}
-----------------------------

Precision and reproducibility of the assay were evaluated using five clinical samples taken from the reference panel and tested in five replicates each. The degree of concordance of drug resistance associated mutations and nucleotide sequence identity was used to estimate the precision and reproducibility.

Phylogenetic analysis {#s2j}
---------------------

Phylogenetic tree was constructed using Neighbor-Joining method [@pone.0105790-Saitou1] in MEGA 5.1 software [@pone.0105790-Tamura1] where the percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown above the branches [@pone.0105790-Felsenstein1]. The evolutionary distances were computed using the Maximum Composite Likelihood method and are in units of number of base substitutions per site. The rate variation among sites was modeled with a gamma distribution (shape parameter = 1).

The reference panel tree had 129 sequences, which included 20 reference panel samples each tested with in-house genotyping assay (n = 20) and ViroSeq genotyping system (n = 20) respectively, 50 sequence data generated from 5 clinical samples, each tested in 5 replicates for precision data (n = 25) and reproducibility data (n = 25) respectively and 39 HIV-1 group M reference sequences obtained from HIV sequence database (<http://www>. hiv. lanl. gov/content/index) maintained by the Los Alamos National Laboratory, University of California, USA. The clinical panel tree comprised of 245 sequences which included 39 HIV-1 subtype reference sequences as described above and 206 clinical panel sequences.

Statistical Analysis {#s2k}
--------------------

The clinical and biological parameter of study subjects in reference and clinical panels are presented in frequency (%) for categorical variables. For quantitative variables, data are presented in mean *±* standard deviation (SD) or median \[Interquartile range (IQR)\]. Prevalence of drug resistance mutations were computed with 95% confidence interval (CI).

### Nucleotide sequence accession numbers {#s2k1}

The GenBank accession number of the sequences generated in this study is KJ185171--KJ185376.

Results {#s3}
=======

Assay design {#s3a}
------------

The present assay is optimized on a nested RT-PCR based protocol to achieve maximum possible sensitivity. The PCR amplicon covered entire protease gene and 1^st^ 300 amino acids of RT gene so as to include all major drug resistance mutations as per the IAS mutation list. The primers used in the study were designed using a database of HIV-1 pol gene sequences reported from India and archived at NCBI GenBank, USA.

Accuracy {#s3b}
--------

The 20 reference panel samples were genotyped using the ViroSeq genotyping system as well as the in-house genotyping assay. The mean nucleotide and amino acid identity between the two tests were 99.21±0.58% and 99.65±0.43% respectively. A total 101 drug resistance mutations were detected by the in-house assay compared to 104 using the ViroSeq genotyping system. A comparative analysis of drug resistance mutations detected by both the methods is described in [**Table 3**](#pone-0105790-t003){ref-type="table"}.

10.1371/journal.pone.0105790.t003

###### Comparison of drug resistance mutations identified by ViroSeq gentyping system and the in-house assay.
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  Sample ID                      Mutations                                                                                                                          
  ------------ --------------------------------------------- ---------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------
  HIV-IN-638                       None                                        None                                        K103N, M184V,Y188L                                              K103N,M184V, Y188L
  HIV-IN-642                       None                                        None                                               None                                                            None
  HIV-IN-648                  M46V, I54V,V82A                            M46V, I54V, V82A                                     K103N, M184V                                                    K103N, M184V
  HIV-IN-652                  L10F, I54V,V82F                            L10F, I54V,V82F                                          T215I                                                          T215I
  HIV-IN-655                  **[L10I]{.ul}**                                  None                                               M184V                                                          M184V
  HIV-IN-661                       A71T                                        A71T                                        K103N, V108I,M184V                                              K103N,V108I, M184V
  HIV-IN-662      L10I, L24I, K43T,M46I, I54V,A71V, V82A      L10I, L24I, K43T,M46I, I54V,A71V, V82A                     A62V, V75I, F77L, Q151M                                        A62V, V75I, F77L, Q151M
  HIV-IN-665       L10V, G48V,**[F53L]{.ul}**, I54V,V82A              L10V, G48V,I54V, V82A                                   K103N, T215Y                                                    K103N, T215Y
  HIV-IN-669                       None                                        None                                     M41L, M184V,Y188L, T215Y                                        M41L,M184V, Y188L,T215Y
  HIV-IN-670                       A71T                                        A71T                                     A98G, M184V,G190A, P236L                                        A98G, M184V,G190A, P236L
  HIV-IN-672                       L10F                                        L10F                                     K65R, K103N,Y181C, M184V                                        K65R, K103N,Y181C, M184V
  HIV-IN-675              I54V, A71V, N88D, L90M                      I54V, A71V,N88D, L90M                                       K70R                                                            K70R
  HIV-IN-678                       None                                        None                                  K65R, K103N,M184V, Y188L,M230L                                 K65R, K103N,M184V, Y188L, M230L
  HIV-IN-679                       None                                        None                                  M41L, K103N,M184V, T215Y,P225H                                 M41L, K103N,M184V, T215Y, P225H
  HIV-IN-683                       L10I                                        L10I                    M41L, D67N,K70R, L74I, A98G,K103N, M184V,T215F, K219Q,P225H   M41L, D67N,K70R, L74I, A98G, K103N, M184V, T215F, K219Q, P225H
  HIV-IN-685    **[L10I]{.ul}**, M46I,I50L, Q58E,V82C, L90M         M46I, I50L,Q58E, V82C,L90M                  M41L, D67N,V75M, K103N,M184V, L210W,T215Y                     M41L, D67N,V75M, K103N, M184V, L210W, T215Y
  HIV-IN-688                       None                                        None                                           V106M, G190A                                                    V106M, G190A
  HIV-IN-690                  G48V, I54V,V82A                            G48V, I54V,V82A                          A98G, F116Y,Q151M, Y181C,M184V, G190A                          A98G, F116Y,Q151M, Y181C, M184V, G190A
  HIV-IN-694                       None                                        None                                               None                                                            None
  HIV-IN-695                    I54V, V82A                                  I54V, V82A                                        Y188L, H221Y                                                    Y188L, H221Y

The discordant mutations are shown in bold and underlined letters.

Sensitivity {#s3c}
-----------

The assay was optimized for amplification of plasma samples having 1000 HIV-1 RNA copies/ml and above. This limit of detection was established by testing a dilution series of 5 samples in triplicates. The assay result is described in [**Table 4**](#pone-0105790-t004){ref-type="table"}. It was found that up to 1000 HIV-1 RNA copies/ml, all replicates of 5 clinical samples amplified successfully but at 500 HIV-1 RNA copies/ml the results were inconsistent.

10.1371/journal.pone.0105790.t004

###### Assay sensitivity results using a dilution series from 5 reference panel samples, each tested in triplicate.
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  Sample ID     Sensitivity at a dilution (HIV-1 RNA copies/ml) of:                             
  ------------ ----------------------------------------------------- -------- -------- -------- --------
  HIV-IN-652                          \+ + +                          \+ + +   \+ + +   \+ + +   − + +
  HIV-IN-655                          \+ + +                          \+ + +   \+ + +   \+ + +   \+ + −
  HIV-IN-665                          \+ + +                          \+ + +   \+ + +   \+ + +   − + −
  HIV-IN-669                          \+ + +                          \+ + +   \+ + +   \+ + +   − − −
  HIV-IN-670                          \+ + +                          \+ + +   \+ + +   \+ + +   \+ − −

"+": Positive amplification; "--": Negative amplification.

Precision and Reproducibility {#s3d}
-----------------------------

All five replicates of 5 clinical samples could be amplified and sequenced successfully. The mean nucleotide sequence identity for precision varied between 99.68±0.16% and 100% whereas the mean nucleotide sequence identity for reproducibility varied between 99.76±0.18% and 100%. The results are summarized in [**Table 5**](#pone-0105790-t005){ref-type="table"}. No discordant drug resistance mutations were detected in the replicate data generated for precision and reproducibility.

10.1371/journal.pone.0105790.t005

###### Reproducibility and precision data of the in-house assay.
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  Sample ID           Plasma ViralLoad (HIV-1RNA copies/ml)   HIV-1Subtype   \% Nucleotidesequence identity   Replicate Tests                      
  ------------------ --------------------------------------- -------------- -------------------------------- ----------------- ---- ---- ---- ---- ---
  Reproducibility:                                                                                                                                 
  HIV-IN-638                         1680600                       C                  100.00±0.00%                   3          3    3    3    3    0
  HIV-IN-661                         875600                        C                  99.81±0.15%                    4          4    4    4    4    0
  HIV-IN-662                         165895                        C                  99.96±0.07%                   11          11   11   11   11   0
  HIV-IN-694                          2100                         A                  99.76±0.18%                    0          0    0    0    0    0
  HIV-IN-695                          1350                         C                  99.84±0.09%                    4          4    4    4    4    0
  Precision:                                                                                                                                       
  HIV-IN-642                         2576440                       C                  99.68±0.16%                    0          0    0    0    0    0
  HIV-IN-652                         1154880                       C                  99.89±0.08%                    4          4    4    4    4    0
  HIV-IN-675                          46544                        C                  99.70±0.21%                    5          5    5    5    5    0
  HIV-IN-683                          12540                        A                  100.00±0.00%                  11          11   11   11   11   0
  HIV-IN-690                          2690                         C                  99.93±0.07%                    9          9    9    9    9    0

The maximum likelihood tree constructed using Mega 5.1 confirmed absence of any sample mix-up or cross contamination and sequences generated from the same sample clustered together ([**Figure 1**](#pone-0105790-g001){ref-type="fig"}).

![Phylogenetic Tree of reference panel samples.\
Phylogenetic analysis of reference panel samples showing exact correlation between in-house assay and the ViroSeq genotyping system. The construction of phylogenetic tree is described in the text. All the HIV-1 subtype reference sequences used to construct the tree were obtained from Los Alamos National Laboratory HIV sequence database (<http://www.hiv.lanl.gov/content/index>). VQ\_ Sample ID: Sequences generated by ViroSeq assay; INHS\_ Sample ID: Sequences generated by in-house genotyping assay; R_Sample ID_A to E represent reproducibility study panel while P_Sample ID_A to E represent precision study panel. The HIV-1 subtype reference sequence IDs shown in the tree are in the following order: subtype.country of origin.isolate number.accession number.](pone.0105790.g001){#pone-0105790-g001}

Clinical Panel result {#s3e}
---------------------

After development of the in-house assay it was used for testing a clinical panel specially created for this purpose. The viral load and CD4+ T cell count of clinical panel samples are described in [**Table 2**](#pone-0105790-t002){ref-type="table"}. Out of the 225 samples, 210 responded successfully to PCR amplification out of which 206 could be successfully sequenced and analyzed for HIV-1 drug resistance mutations. Among 110 samples with viral load of 10^5^ HIV-1 RNA copies/ml of plasma and above, 107 could be successfully amplified and both the DNA strands sequenced. On the other hand, out of 90 samples with viral load in between 10^4^ and 10^5^ HIV-1 RNA copies/ml of plasma, 82 could be successfully amplified but only 80 among them could be sequenced for both the strands. Among 13 samples with viral load in between 5×10^3^ and 10^4^ HIV-1 RNA copies/ml of plasma, 12 could be successfully amplified but double strand DNA sequence could be generated for 11 of them. Among 12 samples with viral load between 10^3^ and 5×10^3^ HIV-1 RNA copies/ml of plasma, 9 could be successfully amplified and double strand DNA sequence could be generated from 8 of them.

Out of 206 samples genotyped, 176 (85.5%), 29 (14.0%) and 1 (0.5%) were from patients infected with HIV-1 subtype C, subtype A and subtype B respectively ([**Figure 2**](#pone-0105790-g002){ref-type="fig"}). Samples from 28 (13.59%) patients did not show any mutations related to HIV-1 drug resistance and 178 (86.41%) of them had at least one HIV-1 drug resistance mutation(s). One hundred and fifty nine (77.18%) samples had at least one NRTI resistance mutation while 161 (78.16%) harbored at least one NNRTI mutation. Samples from 41 (19.90%) patients had at least one PI mutation(s).

![Phylogenetic tree of clinical panel samples.\
Phylogenetic analysis of sequences obtained from clinical panel samples. The construction of phylogenetic tree is described in the text. All HIV-1 subtype reference sequences used to construct the tree were obtained from Los Alamos National Laboratory HIV sequence database (<http://www.hiv.lanl.gov/content/index>). The reference sequence IDs shown in the tree are in the following sequence: subtype.country of origin.isolate number.accession number.](pone.0105790.g002){#pone-0105790-g002}

All three classes of mutations were detected in samples from 29 (14.08%) patients. Among 147 patients on NNRTI and NRTI-based 1st line ART regimen, 116 had mutations belonging to these 2 categories of drugs. M184V was the most common NRTI mutation detected in 132 (64.08%) patients. 76 (36.89%) of the patients harbored at least one Thymidine Analog Mutations (TAMs). The distribution of TAMs in the clinical panel samples were M41L-40 (19.42%), D67N-37 (17.96%), K70R-31 (15.05%), L210W-12 (5.83%), T215F/Y-60 (29.12%) and K219E- 8 (3.88%) respectively. Three or more TAMs were detected in 32 (15.53%) samples while Q151M complex (Q151M, V75I, F77L and F116Y) was observed only in 2 (0.97%) patients. The details of other NRTI related mutations detected in this study are described in [**Figure 3A**](#pone-0105790-g003){ref-type="fig"}.

![NRTI, NNRTI and PI Mutations.\
Frequency of Nucleoside Reverse Transcriptase Inhibitor-related drug resistance mutations \[A\], Frequency of Non Nucleoside Reverse Transcriptase Inhibitors-related drug resistance mutations \[B\] and Frequency of Protease Inhibitors-related drug resistance mutations (including PI major and PI minor drug resistance mutations) \[C\] in 206 patients successfully genotyped from the clinical panel failing 1^st^ line antiretroviral therapy.](pone.0105790.g003){#pone-0105790-g003}

K103N was the most common NNRTI mutation present in 72 (34.95%) patients. The prevalence of other common NNRTI mutations in the study population was K101E/H-24 (11.65%), V106M-20 (9.71%), Y181C/I-49 (23.79%) and G190A/S-39 (18.93%) respectively. The details of other NNRTI-related mutations are described in [**Figure 3B**](#pone-0105790-g003){ref-type="fig"}.

At least one PI major or minor resistance mutations were detected in 23 and 38 patients respectively among the 59 successfully genotyped, who were exposed to ritonavir-boosted PI based 1^st^ line of antiretroviral therapy. Out of this, 20 samples harbored both PI major and minor mutations while 18 and 3 had only PI minor and only PI major mutations respectively. Eighteen samples did not have any PI-related mutations. The most common major PI mutations detected were M46I/L-14 (6.80%), I54A/T/V-16 (7.77%), V82A/C/F-16 (7.77%) and L90M-8 (3.88%) respectively. L10F/I/V-29 (14.08%) and A71T/V-14 (6.80%) were the two common PI minor mutations observed in the clinical panel. The details of other PI-related mutations are described in [**Figure 3C**](#pone-0105790-g003){ref-type="fig"}.

Comparative analysis of cost and hands-on time of in-house assay with ViroSeq genotyping system {#s3f}
-----------------------------------------------------------------------------------------------

[**Table 6**](#pone-0105790-t006){ref-type="table"} describes the hands-on time and cost of different stages of the analysis starting from collection of clinical sample to interpretation of drug resistance mutations. All costs are presented in US dollars. Cost of establishing the reference laboratory capable of performing the assay is however not included in the analysis. Further, some major costs common to both the assays such as logistics and manpower were also excluded. The hands-on times for the ViroSeq genotyping system and the in-house method were 18 hour 45 min and 17 hour 15 min respectively while the running cost of the in-house assay was computed at \$85 compared to \$303 for the ViroSeq genotyping system.

10.1371/journal.pone.0105790.t006

###### Hands - on time and cost comparison between ViroSeq and the in-house HIV-1 genotyping assay.

![](pone.0105790.t006){#pone-0105790-t006-6}

  Process                                  Step(s)                   Assay type                         
  ------------------------ ---------------------------------------- ------------- ------- ------------- ------
  Samplepreparation         Sample collectionand plasma separation     45 min       1.0      45 min      1.0
  Nucleic acidextraction                RNA Extraction                   3 h        250        1 h       7.0
  Amplification                        One step RT-PCR               5 h 30 min            3 h 30 min    15.0
                                          Nested PCR                                       2 h 30 min    5.0
  GelDocumentation                Agarose geleletrophosresis           45 min       2.0      45 min      2.0
  Genotyping                         Ampliconpurification                1 h                   1 h       5.0
                                          Sequencing                 2 h 30 min    30.0    2 h 30 min    30.0
                                Sequence ampliconpurification        1 h 30 min    10.0    1 h 30 min    10.0
                                     Sequencing samplerun            2 h 30 min    10.0    2 h 30 min    10.0
  Sequenceanalysis                 Sequence datavalidation             30 min                30 min     
                                      Sequence assembly                15 min                15 min     
                              Interpretation andquality analysis       30 min                30 min     
  Total                                                              18 h 45 min   303.0   17 h 15 min   85.0

Discussion {#s4}
==========

The HIV-1 drug resistance genotyping assay is not feasible for routine monitoring of patients taking 1^st^ line antiretroviral drugs in resource limited settings like India mainly due to high cost of commercial HIV-1 genotyping assays presently available in the market [@pone.0105790-Aitken2]. But increased access to antiretroviral drugs without proper monitoring results in transmission of drug resistant HIV-1 strains in newly infected individuals [@pone.0105790-Geretti1]. Laboratory methods to monitor the treatment outcome and proper guidelines regarding course of action in case of therapeutic failure is critical in management of HIV-1/AIDS. HIV-1 drug resistance genotyping assay for patients with virologic failure acts as a guiding tool during switching to next line of treatment [@pone.0105790-Saravanan1]. We performed a cost analysis of the drug resistance genotyping assay described in this study and compared it with the running cost of ViroSeq genotyping system which indicated that our assay is around 71.9% cost effective compared to the later. This attribute make this assay more suitable for routine monitoring of transmitted HIV-1 drug resistance strains as well as for detection of drug resistance mutations in patients with virologic failure.

The drug resistance mutations detected by our in-house assay exhibited excellent concordance when compared with corresponding results from the ViroSeq genotyping system. The assay was able to detect all clinically relevant mutations according to the IAS 2013 mutation list [@pone.0105790-Johnson1]. These findings demonstrate both utility and feasibility of this home brew assay in HIV-1 drug resistance surveillance and monitoring in resource limited settings like India.

None of the HIV-1 drug resistance genotyping assays including the US-FDA approved commercial assays as well as various home brew assays can successfully amplify 100% clinical samples mainly due to high genetic variability of HIV-1 [@pone.0105790-Aghokeng1] and occurrence of spontaneous mutation within primer binding regions of the viral genome [@pone.0105790-Korn1]. In this backdrop, the home brew assay described in this study could successfully genotype 91% of samples from the clinical panel which was found to be satisfactory. This high rate of success is possibly due to the geographical region-specific primers designed for this assay coupled with incorporation of a nested PCR protocol.

The in-house assay described in this study was validated as per WHO guidelines for HIV-1 drug resistance genotyping and demonstrated a high degree of precision and reproducibility. The limit of detection of this assay was 1000 HIV-1 RNA copies/ml of plasma sample. This is in line with similar studies from India and other parts of the world [@pone.0105790-Chaturbhuj1]--[@pone.0105790-Zhou1]. The assay has ability to detect all major HIV-1 subtypes (HIV-1 subtype A, B and C) predominant in India [@pone.0105790-Neogi1] as revealed from the clinical panel genotyping results.

The main limitation of this study is the lack of subtype diversity in the reference panel. An ideal panel should comprise of all HIV-1 group M subtypes including circular recombinant forms which were not included here due to scarcity of such samples among HIV-1 sero-positive individuals in India. In spite of this limitation, due to the rigorous validation of assay parameters as per WHO guidelines there is enhanced confidence and reliability seen to be associated with our assay. Genotyping of the clinical panel in this study simulated real time field conditions and demonstrated good performance in detecting all clinically relevant HIV-1 drug resistance mutations in the protease and reverse transcriptase genes. This result is also in line with observations made from other similar studies reporting patterns of HIV-1 drug resistance mutations in patients failing 1^st^ file ART from India [@pone.0105790-Sen1]--[@pone.0105790-Vidya1].

In conclusion, we report development and validation of a low cost HIV-1 drug resistance genotyping assay for resource limited settings like India with potential to serve the increasing demand of HIV-1 genotyping in the HAART *era* for effectively treating HIV/AIDS patients.

The authors are grateful to all the study participants for agreeing to provide their valuable clinical samples for this study.
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